VIDEO: SABCS includes ‘exciting’ research in HR-positive breast cancer
Click Here to Manage Email Alerts
In this video, Payal Shah, MD, assistant professor of medicine at the hospital of the University of Pennsylvania, discusses some of the highlights in hormone receptor-positive breast cancer presented at this year’s San Antonio Breast Cancer Symposium.
“There’s been a lot of exciting things so far in the hormone receptor-positive breast cancer space,” Shah said.
She mentioned results from multiple presentations involving HR-positive breast cancer, including the PALLAS study examining adjuvant palbociclib (Ibrance, Pfizer) in early hormone receptor positive, HER2-negative breast cancer and findings from the MONALEESA studies examining ribociclib (Kisqali, Novartis) in breast cancer subsets.
Reference:
- Carey L, et al. GS2-00. Presented at: San Antonio Breast Cancer Symposium; Dec. 7-10, 2021; San Antonio.
- Gnant M. GS1-07. Presented at: San Antonio Breast Cancer Symposium; Dec. 7-10, 2021; San Antonio.
- O’Shaughnessy J. GS2-01. Presented at: San Antonio Breast Cancer Symposium; Dec. 7-10, 2021; San Antonio.
Collapse
Read more about
Click Here to Manage Email Alerts